DR30206 + oxaliplatin + capecitabine

This is a combination therapy consisting of DR30206, oxaliplatin, and capecitabine. **Oxaliplatin** is a third-generation platinum-based anticancer drug that disrupts DNA synthesis by forming platinum-DNA adducts, leading to cell death through the inhibition of replication and transcription. **Capecitabine** is an oral fluoropyrimidine carbamate that is enzymatically converted to 5-fluorouracil (5-FU) in tumor cells, inhibiting DNA synthesis and cell division. DR30206 is included in the combination, but its identity and mechanism are not described in the available sources; only its code name is provided. The regimen targets rapidly dividing tumor cells and is approved for advanced colorectal, gastric, and other gastrointestinal cancers. The combination enhances antitumor efficacy, improves response rates, and may offer a better side effect profile compared to standard regimens.

Other names

CAPOXXELOX